Mastodon

Glycyrrhizic Acid + Phospholipids (Capsules) Instructions for Use

Marketing Authorization Holder

Pharmstandard JSC (Russia)

ATC Code

A05BA (Drugs for the treatment of liver diseases)

Active Substances

Glycyrrhizinic acid (BP British Pharmacopoeia)

Phospholipids (Group Grouping name)

Dosage Form

Bottle OTC Icon Glycyrrhizic acid + Phospholipids Capsules 35 mg+65 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Capsules are soft gelatin, light brown in color, oval, with a seam, elastic, opaque; the capsule contents are a homogeneous mass from light yellow to dark yellow in color, with a consistency ranging from ointment-like to denser, with a specific odor; slight stratification of the capsule contents is allowed during storage.

1 caps.
Sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) 35 mg
Phospholipids 65 mg

Excipients: beeswax – 36 mg, sunflower oil – a sufficient quantity to obtain capsule contents weighing 450 mg.

Composition of the gelatin capsule shell: gelatin – 106.22 mg, glycerol – 48.93 mg, purified water – 13.6 mg, sodium benzoate E-211 – 0.25 mg, titanium dioxide E-171 – 0.22 mg, dyes: red iron oxide (E-172) – 0.13 mg, yellow iron oxide (E-172) – 0.51 mg, black iron oxide (E-172) – 0.14 mg.

10 pcs. – blister packs (5) – cardboard packs.

Clinical-Pharmacological Group

Hepatoprotective agent with immunomodulatory and antiviral action

Pharmacotherapeutic Group

Hepatoprotective agent

Pharmacological Action

Hepatoprotective agent, also possesses antiviral activity.

Glycyrrhizic acid suppresses virus reproduction in the liver and other organs due to its stimulating effect on interferon production, increasing phagocytosis, and enhancing the activity of natural killer cells. Due to its detergent action, it improves the emulsification of phosphatidylcholine in the intestine.

Phosphatidylcholine is the main structural component of the phospholipid layer of biological membranes (cellular and intracellular). It restores the structure and function of damaged hepatocyte membranes, thereby preventing the loss of enzymes and other active substances by the cells, normalizes protein, lipid, and fat metabolism, restores the detoxification function of the liver, suppresses the formation of connective tissue in the liver, and reduces the risk of fibrosis and cirrhosis of the liver.

Pharmacokinetics

The components of this combination are well absorbed in the small intestine both in the form of the original molecule and as biologically active products of their hydrolysis by digestive enzymes (unsaturated fatty acids, glycerol, inorganic phosphate and choline, glycyrrhetinic acid), which are transported through the intestinal wall into the lymphatic system, easily penetrate the liver, lungs, skin, and other organs.

Partial resynthesis of phosphatidylcholine from hydrolysis products occurs in the liver.

Indications

As part of complex therapy: acute and chronic hepatitis; fatty hepatosis and other degenerative liver lesions; drug-induced and alcoholic liver lesions; liver cirrhosis; intoxications; psoriasis; neurodermatitis; eczema.

ICD codes

ICD-10 code Indication
B15 Acute hepatitis A
B16 Acute hepatitis B
B17.1 Acute hepatitis C
B18.0 Chronic viral hepatitis B with delta-agent
B18.1 Chronic viral hepatitis B without delta-agent
B18.2 Chronic viral hepatitis C
K70 Alcoholic liver disease
K71 Toxic liver disease
K73 Chronic hepatitis, not elsewhere classified
K74 Fibrosis and cirrhosis of liver
K76.0 Fatty (change of) liver, not elsewhere classified
L20.8 Other atopic dermatitis (neurodermatitis, eczema)
L28.0 Lichen simplex chronicus (circumscribed neurodermatitis)
L30.0 Nummular eczema
L40 Psoriasis
ICD-11 code Indication
1E50.0 Acute hepatitis A
1E50.1 Acute hepatitis B
1E50.2 Acute hepatitis C
1E51.0Z Chronic hepatitis B, unspecified
1E51.1 Chronic viral hepatitis C
1E51.2 Chronic hepatitis D
4A85.00 Drug hypersensitivity-induced liver disease
9A06.70 Atopic eczema of the eyelids
DB92.0 Non-alcoholic fatty liver disease without steatohepatitis
DB92.Y Other specified non-alcoholic fatty liver disease
DB92.Z Non-alcoholic fatty liver disease, unspecified
DB93 Fibrosis or cirrhosis of liver
DB94.Z Alcoholic liver disease, unspecified
DB95.Z Drug-induced or toxic liver disease, unspecified
DB97.2 Chronic hepatitis, not elsewhere classified
EA80.0 Infantile atopic eczema
EA80.1 Childhood atopic eczema
EA80.2 Adult atopic eczema
EA80.Z Atopic eczema, unspecified
EA82 Nummular dermatitis
EA83.00 Lichen simplex of vulva
EA83.01 Lichen simplex of male genital organs
EA83.02 Lichen simplex of perianal area
EA83.0Z Lichen simplex of unspecified location
EA85.20 Atopic hand eczema
EA90.Z Psoriasis, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Take the capsules orally with meals, swallowing whole with a small amount of water.

The standard adult dosage is 2 capsules taken three to four times daily.

For acute conditions, initiate therapy at the higher frequency of four times daily.

For chronic liver diseases, maintain the prescribed dosage for the full duration of therapy.

The duration of treatment is determined by the physician based on the disease severity and clinical response.

For parenteral administration, administer the solution intravenously and slowly.

The single IV dose is administered twice daily, in the morning and evening.

The typical course of IV therapy is 10 days.

Following the IV course, switch to oral administration of the capsules to continue treatment.

Do not adjust the dosage or frequency without medical consultation.

Adverse Reactions

Allergic reactions skin rash.

Contraindications

Hypersensitivity to the components of the combination.

Use in Hepatic Impairment

The drug is approved for use in liver dysfunction

Drug Interactions

The solution for parenteral administration should not be mixed with solutions of other medicinal products.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS